Can a Low-Carb diet calm kidney disease inflammation?
NCT ID NCT07651397
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a low-carbohydrate, plant-based diet can lower inflammation in people with autosomal dominant polycystic kidney disease (ADPKD). Thirty-six adults will try the special diet and their usual diet in random order, each for 12 weeks. The main goal is to see if the diet reduces a urine marker of kidney inflammation called MCP-1.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- carbohydrate-restricted, plant-dominant diet
- What this could lead to
- If this works, it could point toward a dietary approach to slow kidney disease progression in ADPKD by reducing inflammation.
- What could go wrong
- This is a small, early-stage trial (36 people) testing a biomarker, not kidney function directly. The diet may be hard to follow, and results may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 36 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥18 2. Diagnosis of ADPKD based on established clinical or genetic criteria (PKD 1/PKD2) 3. Estimated glomerular filtration rate (eGFR) between 45 and 90 mL/min/1.73 m² 4. Mayo Imaging Classification class 1C-1E based on MRI-derived height-adjusted total kidney volume. 5. Stable kidney function, defined as no acute kidney injury and no decline in eGFR \>20% within the preceding 3 months 6. Stable antihypertensive and chronic medications for at least 4 weeks prior to enrollment 7. Ability and willingness to adhere to the prescribed dietary intervention 8. Ability to provide written informed consent Exclusion Criteria: 1. eGFR \<45 mL/min/1.73 m² or requirement for dialysis 2. History of kidney transplantation 3. Significant albuminuria, defined as urine albumin to creatinine ratio (UACR) \>300 mg/g 4. Poorly controlled or unstable diabetes mellitus (e.g., HbA1c \>8% or clinically significant glycemic variability or frequent hypoglycemia) 5. Use of Tolvaptan at the time of screening or within the study period 6. Current adherence to a ketogenic or carbohydrate restricted diet 7. Unintentional weight loss \>5% within the preceding 3 months 8. Active infection, inflammatory disease, or malignancy that may influence inflammatory markers 9. Current use of systemic corticosteroids or immunosuppressive therapy 10. Active or symptomatic nephrolithiasis 11. Serum bicarbonate \<20 mmol/L 12. Pregnancy or breastfeeding 13. Known eating disorder or condition limiting adherence to dietary interventions 14. Participation in another interventional study within the previous 3 months 15. Any condition that, in the opinion of the investigators, would interfere with study participation or interpretation of results
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney disease (adpkd) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a kidney disease drug alter birth control?
- Large study tracks kidney disease progression in thousands of patients
- New hope for dialysis patients: non-surgical kidney reduction could clear the way for transplant
- Could a drug for acromegaly protect kidneys in polycystic disease?
- Drug interaction study: VX-407 and oral contraceptives
- Could a keto diet help slow kidney disease? new study seeks answers